Literature DB >> 15683597

Statin use in the metabolic syndrome.

Justin B Lundbye1, Paul D Thompson.   

Abstract

The metabolic syndrome is a condition associated with obesity, insulin resistance, hypertension, dyslipidemia, hypercoagulability, and chronic inflammation, all of which increase the risk of cardiovascular disease (CVD). The Third National Cholesterol Education Program Adult Treatment Panel extensively discussed the metabolic syndrome because it is a major health issue in the United States due to the national epidemic of obesity. Statins cause significant CVD risk reduction in patients with the metabolic syndrome by alterations in lipid levels and possibly by decreasing inflammation. Because of the increased CVD risk associated with the metabolic syndrome and extensive clinical trial evidence documenting reduction of CVD risk with statin treatment, all patients with the metabolic syndrome should be evaluated as candidates for statin treatment as part of a multidisciplinary approach to reduce CVD risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15683597     DOI: 10.1007/s11883-005-0070-9

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  50 in total

1.  Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry.

Authors:  K Miura; M L Daviglus; A R Dyer; K Liu; D B Garside; J Stamler; P Greenland
Journal:  Arch Intern Med       Date:  2001-06-25

2.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

Review 3.  Insulin resistance--mechanisms, syndromes, and implications.

Authors:  D E Moller; J S Flier
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

4.  Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction.

Authors:  J E Buring; G T O'Connor; S Z Goldhaber; B Rosner; P N Herbert; C B Blum; J L Breslow; C H Hennekens
Journal:  Circulation       Date:  1992-01       Impact factor: 29.690

5.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

6.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

7.  Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients.

Authors:  Birgit Nyholm; Michael F Nielsen; Kurt Kristensen; Søren Nielsen; Torben Østergård; Sten B Pedersen; Thomas Christiansen; Bjørn Richelsen; Michael D Jensen; Ole Schmitz
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  IL-1 produced and released endogenously within human islets inhibits beta cell function.

Authors:  M Arnush; M R Heitmeier; A L Scarim; M H Marino; P T Manning; J A Corbett
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

10.  Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.

Authors:  David E Kelley; Lewis H Kuller; Therese M McKolanis; Patricia Harper; Juliet Mancino; Satish Kalhan
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

View more
  4 in total

1.  Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.

Authors:  W Verreth; D De Keyzer; P C Davey; B Geeraert; A Mertens; M-C Herregods; G Smith; F Desjardins; J-L Balligand; P Holvoet
Journal:  Br J Pharmacol       Date:  2007-03-26       Impact factor: 8.739

2.  Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome.

Authors:  Hyo Sun Lee; Chang Hee Jung; Sung Rae Kim; Hak Chul Jang; Cheol Young Park
Journal:  Endocrinol Metab (Seoul)       Date:  2016-03

3.  Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells.

Authors:  Makoto Seo; Ikuo Inoue; Masaaki Ikeda; Takanari Nakano; Seiichiro Takahashi; Shigehiro Katayama; Tsugikazu Komoda
Journal:  PPAR Res       Date:  2008-12-24       Impact factor: 4.964

4.  Dyslipidemic drugs in metabolic syndrome.

Authors:  Sheelu S Siddiqi; Farida Ahmad; Syed Z Rahman; Asad U Khan
Journal:  Indian J Endocrinol Metab       Date:  2013-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.